Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Plinabulin Earns FDA Fast Track Status for Advanced NSCLC After ICI Failure

30 September 2026 · By · Wire by Fusion42

Published

30 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 30 September 2026 · Fusion42 review

Plinabulin, combined with docetaxel, has earned FDA Fast Track designation for treating advanced non-small cell lung cancer (NSCLC) after failure of immune checkpoint inhibitor (ICI) therapy.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The FDA's Fast Track for plinabulin opens regulatory doors in tough lung cancer cases. Biotech founders focusing on post-ICI lung cancer treatments gain a new pathway to accelerate clinical approval.

◆ Coverage

1 source · 30 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-fast-trackoncologynsclcdrug-approvalclinical-trials